Stivarga: a new oral multikinase inhibitor

Stivarga (regorafenib) is indicated in metastatic colorectal cancer previously treated with fluoropyrimidine-based chemotherapy, anti-VEGF therapy and anti-EGFR therapy, or when these therapies are not suitable.

The recommended dose of Stivarga is 160mg once daily after a light low-fat meal on days 1-21 of a 28-day treatment cycle
The recommended dose of Stivarga is 160mg once daily after a light low-fat meal on days 1-21 of a 28-day treatment cycle


Regorafenib is an oral tumour deactivation agent that inhibits multiple protein kinases, including those involved in tumour angiogenesis, oncogenesis and the tumour microenvironment.1,2


The safety and efficacy of regorafenib were evaluated in the double-blind, phase III CORRECT study involving 760 patients with metastatic colorectal cancer that had progressed after failure of standard therapy.1,2

Patients were randomised to receive best supportive care plus regorafenib 160mg (n=505) or placebo (n=255) once daily for the first 3 weeks of each monthly treatment cycle. Treatment was continued until disease progression or unacceptable toxicity occured. The primary outcome measure was overall survival.1,2

Survival increased

Regorafenib produced a significant improvement in overall survival compared with placebo, of 6.4 versus 5 months (HR 0.77, 95% CI 0.64–0.94, p=0.0052). A significant improvement in progression-free survival, a secondary endpoint, was also observed (HR 0.494, p<0.000001).1,2

Safety profile

The most common adverse effects observed in patients receiving regorafenib were hand-foot skin reaction, fatigue, diarrhoea, hypertension and rash.1,2


  1. Stivarga Summary of Product Characteristics, August 2013.
  2. Grothey A et al. Lancet 2013; 381: 303–12.

View Stivarga drug record

Further information: Bayer plc

Follow MIMS on Twitter

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

More from MIMS

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

A healthcare professional holds a syringe in one hand while pinching a baby's thigh as they prepare to administer a vaccination.

Changes to routine vaccination schedule recommended by JCVI

The Joint Committee on Vaccination and Immunisation...

Drug price changes - live tracker

EXCLUSIVE TO SUBSCRIBERS Use our constantly updated...

New and deleted indications - live tracker

EXCLUSIVE TO SUBSCRIBERS See the latest changes to...